The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
One task, one interaction, one pair, experts advocate
The protections extend through at least 2035, with the potential for further extensions
Subscribe To Our Newsletter & Stay Updated
